Piper Sandler conferences and events are by invitation only. If you wish to attend, please contact your Piper Sandler representative.

As CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications, the 2nd RNA Editing Summit returns to help you accelerate the translation and commercialization of RNA editing for an array of research and therapeutic applications. This virtual conference focuses specifically on the latest approaches in RNA-editing...

MassBio’s President & CEO, Bob Coughlin, will host a regular virtual Town Hall for members. This will be an opportunity for our members to ask questions, hear what MassBio is up to, and learn more about the state of the industry amidst the COVID-19 pandemic. This Town Hall will feature Matthew Harrison, a Managing Director and...

Join BIO and LaVoieHealthScience for our next Global Market View webinar on December 1 at 10:30AM ET. Our panel of industry leaders with share their perspectives on several topics including private, public, US, EU and China markets, JPM virtual week, the 2020 election, new company formation, year-end regulatory reviews and record financing through NewCo IPO's,...

The prospect of raising capital for early stage companies (pre-seed to Series A) in times of uncertainty always present challenges. Funders continue to invest in companies they have worked with previously, but for the first time entrepreneur or the novice team attracting the right type of capital, the process is longer and more arduous. But...

Important news! After carefully monitoring the global COVID-19 situation over recent months and out of concern for the health and well being of all our attendees, sponsors, and staff, we have decided on a different format for this year’s Scrip Awards. For the first time ever, the Scrip Awards is going digital! We are delighted...

Executive leaders from leading next-generation biotechnology companies will provide exclusive insights into their personal quests for funding the growth of innovation. We will explore where they went right, when they took the wrong turn, what they never expected, and how they would chart a different course for the journey. From the initial concept, to building...

Global Health Authorities have long recognized the need to facilitate development and minimize delays in patient access for novel treatments intended for serious and life-threatening disease. Over the past decade, FDA, EMA and PMDA have launched various “expedited programs” to foster collaboration with industry in the delivery of these promising new therapies. This speaker series will...

A new product launch, a clinical study, or regulatory submission are all examples of projects in life sciences. In performing their jobs, PMs in the life sciences are taking on more cross-functional responsibilities. And while asked to wear many hats, they must still ensure the final product or program is delivered on time, within budget,...